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Abstract
The circadian rhythm controls a range of important biological behaviors with a
24-hour cycle. The mammalian biological clock is a layered network of vibrators with
a master clock locating in the neurons of suprachiasmatic nucleus (SCN) in the
hypothalamus and a set of core and related circadian genes. Several lines of evidence
from previous studies suggested the relationships between tumorigenesis and
circadian rhythm disruption. However, the effects of circadian genetic factors in
cancer survival remains uncertain. Therefore, it is important to review and explore the
circadian genetic factors which might be linked to cancer survival. This paper aimed
to evaluate the potential associations between circadian genetic factors and cancer
survival by summarizing 30 epidemiological studies and searching 2 databases. The
circadian genetic factors identified included both gene expression and SNPs. Our
results showed that 16 circadian genes, PER1, PER2, PER3, CRY1, CRY2, BMAL1,
CLOCK, NPAS2, NPAS3, TIMELESS, RORA, RORC, NR1D2, CK1ε, DEC1 and
TIPIN, were significantly related to cancer survival across several types of cancer.
The associations between circadian genes and cancer survival differed among
different genes and cancer types.
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Introduction
Circadian rhythm controls a wide range of important biological behaviors in a 24hour cycle, which responds to light and darkness, and affects many organisms,
including animals, plants and microorganisms. In mammals, the biological clock
controls all aspects of physiology, including sleep, metabolism and the regulation of
the immune system. (Rijo-Ferreira, 2019) The mammalian biological clock is a
layered network of vibrators with a master clock locating in the neurons of
suprachiasmatic nucleus (SCN) of the anterior hypothalamus. SCN is entrained by the
light-dark cycle and synchronizes the phases of multiple peripheral clocks in different
peripheral tissues. (Reppert and Weaver, 2002)
At the molecular level, circadian clocks are cellular autonomic and involve a core
set of circadian genes, which are implicated in susceptibility and prognosis of cancers
by involving in the regulation of DNA damage and repair, carcinogen metabolism and
detoxification, cell proliferation, apoptosis, and cell cycle. (Zmrzljak and Rozman,
2012) The primary circadian clock pathway genes in mammals are involved in
transcriptional self-regulating feedback loop, including CLOCK, Brain and Muscle
ARNT-Like 1 (BMAL1), period 1 (PER1), period 2 (PER2), cryptochrome 1 (CRY1),
cryptochrome 2 (CRY2), REV‐ERBα (also known as NR1D1), RORA, and casein
kinase 1-epsilon/ delta (CK1ε/δ) (Buhr et al., 2013). CLOCK/BMAL1 heterodimer
forms the positive elements of the central oscillatory loop, which is thought to be the
basis of circadian rhythms. (Gekakis et al., 1998) The main driver of circadian
rhythms pivots around the E-box-mediated negative feedback loop, in which Period

(PER) and Cryptochrome (CRY) proteins inhibit the complex CLOCK/BMAL1
transcription activity. (Buhr and Takahashi, 2013) CLOCK/BMAL1 also controls the
transcription of Rev-ERBα to periodically suppress BMAL1 expression, creating an
additional feedback loop. (Preitner et al., 2002) In summary, fluctuations in the
expression of multiple genes explain the 24-hour circadian rhythms of physiological
processes. (Panda and Hogenesch, 2004)
Circadian rhythms play an important role in human health. Studies have stated the
role of it in affecting sleep, aging, cancer and vascular systems. (Jagannath et al.,
2013; Scheiermann et al., 2018; Kondratov et al., 2006; Kettner et al., 2014; Paschos
and FitzGerald, 2010) However, the increase in the amount of unnatural light during
the day and at night brought about by a modern industrialized lifestyle disrupts the
homeostasis, which is suggested by external circadian rhythms. For cancer, several
lines of evidence from previous studies suggested the relationships between cancer
risk and circadian rhythm disruption. According to several studies, an increased risk
of breast cancer was found among shift workers. (Davis et al., 2001; Schernhammer et
al., 2001; Lie et al., 2006) The significant associations between breast cancer and 3
single-nucleotide polymorphisms in CRY2 (rs11038689, rs7123390, and rs1401417)
were identified. (Hoffman et al., 2010) Chu et al. found suggestive associations
between prostate cancer risk and NPAS2 variants in men using finasteride, and SNP
rs746924 remained statistically significant after Bonferroni correction (OR = 1.5, P =
9.6 × 10-5). (Chu et al., 2018) In a case-control study in China, gene-based analysis
highlighted a significant association between RORA and colorectal cancer risk. (Gu et

al., 2018)
Since genetic polymorphisms and changes in expression of circadian genes are
considered strongly related with increased disease risk, genetic variations in circadian
rhythms have been deeply researched in many epidemiological studies. Nonetheless,
to date, only a few epidemiological studies have investigated the relationship between
circadian genetic factors and cancer survival outcomes compared to cancer
susceptibility. Therefore, there is a need to timely review the latest epidemiological
studies on rhythm genes and cancer survival outcomes in order to expand knowledge
about candidate cancer genes.

Methods
I have systematically searched the PubMed database using keywords “cancer” or
“tumor” or “leukemia” or “carcinoma” or “lymphoma” or “melanoma” and
“circadian” and “survival” for studies published until Mar 2021. The initial search
identified 653 publications in the English language. Thirty papers of them met the
criteria of having an epidemiological focus on cancer and examing the associations
between genetic circadian factors and cancer survival. The following data was
extracted from these studies: cancer type, circadian genetic factors, related health
outcome, sample size, hazard ratio and p-value, tissue type, PMID and authors.
I also searched Gene Expression database of Normal and Tumor tissues 2
(GENT2) and Kaplan-Meier plotter for public circadian gene expression data to
assess the effect of gene expression on survival in different cancer types. (Nagy et al.,

2021) By entering gene symbols of circadian genes and choosing tissue types,
GENT2 and Kaplan Meier plotter will output Kaplan-Meier survival analysis and
compare gene expression levels in tumor tissues. I assessed the expression level of
PER1, PER2, PER3, CRY1, CRY2, BMAL1, CLOCK, NPAS2, NPAS3, TIMELESS,
RORA, RORC, NR1D2, CK1ε, DEC1 and TIPIN on overall survival in all cancer
types, and presented the significant results. The number of patients with available
clinical data for each cancer type was shown in Table 1. Patients’ expression levels of
circadian genes were split by median. GENT2 is freely available at
http://gent2.appex.kr, and Kaplan-Meier plotter is freely available at
https://kmplot.com/analysis/.

Results
Thirty epidemiological studies on circadian genetic factors and cancer survival
have been conducted since 2009, and all of them reported significant relationships.
The statistically significant associations between PERs, CRYs, BMAL1, CLOCK,
NPASs, TIMELESS, RORA, RORC, NR1D2, CK1ε, DEC1 and TIPIN and cancer
survival were indicated in 16 cancer types, including breast cancer, colorectal cancer,
pancreatic cancer, gastric cancer, liver cancer, kidney cancer, endometrial cancer, lung
cancer, prostate cancer, cervical cancer, diffuse large B-cell lymphoma, oral squamous
cell carcinoma, head and neck squamous cell carcinoma, nasopharyngeal carcinoma,
metastatic melanoma and soft tissue sarcoma (Table 2). All of the primary circadian
genes were reported to play a role in cancer survival. The genetic factors investigated

included both gene expression and variants. Most of them were gene expression, and
10 were gene variants.
Among 16 cancer types, survival outcomes of colorectal cancer, breast cancer,
pancreatic cancer, kidney cancer, gastric cancer and liver cancer were found
associated more than 5 genetic circadian factors (Figure 1A). Colorectal cancer was
researched most, by 10 papers, and its survival was linked to 9 genetic circadian
factors (Figure 1A and 1B). The significant findings between expression of CLOCK,
CRY2 and NPAS2 and breast cancer survival, expression of CRY1 and PER3 and
colorectal cancer survival, as well as expression of CRY2 and pancreatic cancer
survival were indicated more than once and showed consistent results (Table 2).
Cadenas et al. reported that higher expression of CRY2 was associated with better
metastasis free survival of breast cancer, and Mao et al. found it was linked to longer
overall survival. (Cadenas et al., 2014; Mao et al., 2015) For patients with colorectal
cancer, higher expression of CRY1 was observed to have longer overall survival and
higher five-year survival rate (Yu et al., 2013; Hasakova et al., 2018). Yu et al.
reported that the 5-year survival rate of the high CRY1 expression group was 74.7%,
which was significantly lower than that of the low expression group (89.1%). (Yu et
al., 2013) According to Relles et al. and Qiu et al., higher percent survival at 2 years
and longer overall survival of pancreatic cancer were related to higher expression of
CRY2. The percent survival at 2 years of patients with low CRY2 expression was
22.3%, while that of patients with high expression was 43.9%. (Relles et al., 2012)
Expression and variants of these genes were observed to have positive or negative

effect on cancer survival (Figure 2). Higher expression of PER1, PER2, PER3, CRY2,
BMAL1, CLOCK, NPAS2, TIMELESS, RORA, RORC, NR1D2, CK1ε and TIPIN
showed protective effects on cancer survival. By contrast, homogeneous expression of
PER2 or BMAL1, and higher expression of CRY1, TIMELESS and DEC1 indicated
negative effects on cancer survival. Interestingly, expression of PER1, PER2, PER3,
CRY2, BMAL1, CLOCK, NPAS2, TIMELESS and RORA were associated with more
than one cancer type. Besides, for the same gene, consistent directions of its effect
were found across different cancer types. Higher expression of PER1 was related to
better cancer survival in 6 cancer types, including breast cancer, colorectal cancer,
pancreatic cancer, kidney cancer, endometrial cancer, and non-small cell lung cancer.
Expression of PER2, PER3, and CRY2 was associated with survival of 5 different
types of cancer. Expression of BMAL1, CLOCK and NPAS2 was related to 4 types of
cancer, as well as expression of RORA was linked to 2 types of cancer. However,
significantly shorter survival was associated with higher expression of TIMELESS in
patients having breast cancer, liver cancer, kidney cancer, lung cancer, cervical cancer.
Thirteen single nucleotide polymorphisms (SNPs) were recognized in PER1,
PER2, PER3, CRY1, CLOCK, NPAS2, NPAS3 and RORA, indicating several
statistically significant associations between circadian SNPs and cancer survival. SNP
rs3027178 in PER1, SNP rs7602358 in PER2, SNP rs228729 in PER3, SNP
rs11133399 in CLOCK, SNP rs2279284 in BAML1, SNP rs1053096 in NPAS2 and
SNP rs2305160 in NPAS3 posed negative effects on patients’ survival with cancer.
SNP rs3027178 in PER1, SNP rs228729 in PER3, SNP rs11133399 and SNP

rs2279284 in BAML1 in CLOCK were significantly related to an increased death risk
in gastric cancer patients. (Qu et al., 2016; Chen et al., 2019) Epidemiological study
of Yuan et al. indicated that SNP rs1053096 in NPAS2 and SNP rs2305160 in NPAS3
increased overall death risk of hepatocellular carcinoma patients in the recessive
model and the dominant model. (Yuan et al., 2014) In soft tissue sarcoma, SNP
rs7602358 in PER2 had detrimental effects on patients’ survival. (Benna et al., 2018)
On opposite, SNP rs2640908 in PER3, SNP rs1056560 in CRY1, SNP rs3749474
and SNP rs1801260 in CLOCK, SNP rs1044432 in BAML1 and SNP rs76436997 in
RORA had significant protective effect on cancer survival. In hepatocellular
carcinoma, patients who carried at least one variant allele of SNP rs2640908 in PER3
had a significantly decreased risk of death compared with those carrying homozygous
wild-type alleles (11.6 months vs. 8.1 months). (Zhao et al., 2012) SNP rs1056560 in
CRY1 and SNP rs1044432 in BAML1 exhibited a significant protective effect on the
overall survival in patients with gastric cancer. (Qu et al., 2016; Chen et al., 2019) For
colorectal cancer patients, SNP rs3749474 and SNP rs1801260 in CLOCK and SNP
rs76436997 in RORA increased their overall survival time. (Gu et al., 2018; Zhou et
al., 2012)
The significant results of Kaplan Meier survival analysis using GENT2 database
are shown in Fig. 3. The overall survival of patients in 7 cancer types (breast cancer,
blood cancer, brain cancer, lung cancer, ovarian cancer, colon cancer and stomach
cancer) were associated with circadian gene expression levels. In this analysis,
expression of PER2, PER3, CRY2, NR1D2, CLOCK and NPAS3 did not show

detrimental effects on cancer survival. Interestingly, expression of PER2, PER3,
CRY2, NR1D2, CLOCK also only indicated protective effects on cancer survival
among the types of cancer that have been studied in my review. Among these six
genes, high PER2 expression levels were related to significantly better overall
survival in 4 types of cancer, including breast cancer, blood cancer, brain cancer and
ovarian cancer. High expression of PER3 were linked to significantly better overall
survival in patients with breast cancer, blood cancer and brain cancer. PER1, CRY1,
BMAL1, NPAS2, RORA, RORC, DEC1 and TIPIN showed different effects (protective
or detrimental) on overall survival in different cancer types. What’s more, patients
with breast cancer in the high PER1, PER2, PER3, CRY2 and RORC expression group
had significant longer overall survival than those in the low expression group. The
result was consistent with Cadenas et al.’s study which also indicating the protective
effects of PER1, PER2, PER3, CRY2 and RORC in breast cancer survival.
I also performed the Kaplan Meier survival analysis to assess the effects of
circadian genes on survival in 21 cancer types using Kaplan-Meier plotter database.
The complete results were provided in the Supplemental Figures. Figure 4 showed the
results of PER2, PER3, RORA, RORC, DEC1 and TIMELESS. PER2, PER3, RORA
and RORC did not showed significantly negative effects on survival in these 21 types
of cancer. PER2 was found associated with survival of kidney renal clear cell
carcinoma and pancreatic ductal adenocarcinoma. PER3 was related to survival of
kidney renal clear cell carcinoma and cervical squamous cell carcinoma. RORA had
significantly protective effects on kidney renal clear cell carcinoma, kidney renal

papillary cell carcinoma and lung adenocarcinoma. Compared with low expression
group, high expression levels of RORC indicated longer overall survival in patients
with kidney renal clear cell carcinoma, esophageal adenocarcinoma, bladder
Carcinoma, liver hepatocellular carcinoma, thymoma and thyroid carcinoma. On the
contrary, DEC1 only showed significantly detrimental effects in this analysis, and
high expression of DEC1 was correlated with worse overall survival in kidney renal
clear cell carcinoma and lung adenocarcinoma. Besides, TIMELESS was observed to
play a protective or detrimental role based on different cancer types. High expression
of TIMELESS suggested significantly longer overall survival in patients with kidney
renal clear cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma or
sarcoma. For cervical squamous cell carcinoma, stomach adenocarcinoma thyroid
carcinoma, thymoma and esophageal squamous cell carcinoma, patients with high
expression had significantly shorter overall survival than those with low levels of
expression.

Discussion
In this study, I reviewed and investigated the associations between circadian
genetic factors and cancer survival across different cancer types. According to my
review of 30 papers, PER1, PER2, PER3, CRY1, CRY2, BMAL1, CLOCK, NPAS2,
NPAS3, TIMELESS, RORA, RORC, NR1D2, CK1ε, DEC1 and TIPIN were
significantly related to patients’ survival in 16 types of cancer, including breast
cancer, colorectal cancer, pancreatic cancer, gastric cancer, liver cancer, kidney

cancer, endometrial cancer, lung cancer, prostate cancer, cervical cancer, diffuse large
B-cell lymphoma, oral squamous cell carcinoma, head and neck squamous cell
carcinoma, nasopharyngeal carcinoma, metastatic melanoma and soft tissue sarcoma.
The results of the review are consistent, indicating that circadian genes may play a
role in cancer survival. Furthermore, I conducted survival analysis using GENT2 and
Kaplan-Meier plotter database, which also indicated what expression level of
circadian genes was significantly associated with cancer overall survival.
Our results suggested that the associations between circadian genes and cancer
survival differed among different genes and cancer types. Circadian genes may act
dissimilar roles in different tumor environments and organisms, showing the
complexity of the circadian transcriptional loops. For example, TIMELESS was
associated with poorer survival in patients with ovarian cancer but better survival in
cervical squamous cell carcinoma, while others, such as PER2 and PER3, were
associated with better survival in patients with kidney renal clear cell carcinoma.
TIMELESS is known to be a positive regulator of DNA replication and TIMELESSTIPIN functions as a replication fork stabilizer. (Leman et al., 2010) TIMELESS
depletion increases γH2AX and causes G2 / M arrest, restricting cell proliferation.
Activation of ERK can lead to the over-expression of TIMELESS in cancer, which
stimulates the proliferation of cancer cells. (Neilsen et al., 2019) Differently, P53 is an
important anti-cancer gene, and previous studies have shown that reducing the
expression of PER2 can directly depress the activation of P53 protein, thus
accelerating the development of tumor. (Fu et al., 2002) However, the exact molecular

mechanisms behind the complex clock mechanism are still largely unknown. Further
confirmation of the complex function of the biological circadian rhythm in cancer is
needed in the future.
The circadian genetic factors identified included both gene expression and SNPs.
SNPs can cause disruption to circadian rhythms and alterations in gene expression,
but a single SNP may provide moderate or undetectable effects. Besides, the analysis
of SNPs needs reference alleles. When genotype or frequency data are available, it
may only be known which allele is dominant and which allele is minor in a particular
population. As a result, interpretation of polymorphism varies, depending on the type
of cancer or the population in which it is being evaluated. Relatively, gene expression
is related to the function of genes, and its biological significance is easier to be
interpreted. However, the examination of SNPs is relatively convenient. Venous blood
is the most commonly sampled specimen and can be easily obtained by venipuncture,
while the examination of gene expression usually needs tissue samples. It is suggested
to test the association between SNP and disease more effectively by jointly modeling
the relationship between SNP, gene expression and disease. (Huang et al., 2014)
Overall, these results need to be interpreted with caution and further validated in more
studies.
However, there existed some inconsistent results between the review and the
public databases. Zhang et al. revealed that an increase in the expression of
TIMELESS was linked to poorer overall survival and disease-free survival in earlystage cervical carcinoma. (Zhang et al., 2016) Our results based on Kaplan-Meier

plotter database suggested that higher expression of TIMELESS was related to
significantly better overall survival in patients with cervical squamous cell carcinoma.
The discrepancy of the results may be partly explained by different tumor subtypes or
stages. Several CLOCK genes were differentially expressed between tumor stages and
showed significant differences in different patient subtypes within cancer types,
suggesting that CLOCK genes may be altered during tumor progression. (Ye et al.,
2018) Different tumor subtypes or stages may have different genomic patterns and
influence the relationship between circadian genes and prognosis. The studies used
different study population. In Zhang et al.’s study, tumor specimens were collected
from 189 patients with cervical cancer who underwent surgical treatment in the
Cancer Center of Sun Yat-sen University from 2006 to 2010. (Zhang et al., 2016)
GENT2 used gene expression profiles from more than 34,000 samples of different
human cancer and normal tissues generated by the Affymetrix U133A or U133Plus2
microarray platform. (Park et al., 2019) Besides, the study population may have
different treatment of cancer after surgery, which can also become a confounder.
What’s more, in the review, all the associations between circadian factors and cancer
survival were significant. However, in the study using GENT2 and Kaplan-Meier
plotter, quite a number of the results between circadian factors and cancer survival
were not significant. It may be due to the publish bias that authors publish only results
that show a significant finding disturbs the balance of findings.
This study had several limitations. Most of the significant associations were not
replicated more than once. Besides, the study did not stratify tumors according to

stages and molecular subtypes. There are still huge gaps in the understanding of the
association between circadian genes and different types of cancer, different subtypes
of cancer, and different stages of cancer. What’s more, the timing of the acquisition of
biological samples from cancer patients is unknown, which may result in significant
differences in the omics data. (Ye et al., 2018) Because the results lack complete
consistency, these potential biomarkers should not be used to make clinical decisions
related to cancer treatment at this time. However, these findings warrant the need for
further research and make the area a focus of research. Future research fields of the
clinical implications of circadian genetic factors may include indicating survival,
serving as potential treatment targets and supporting cancer chrono therapy.
With the development of genomic technology, molecular diagnosis has been
widely used in cancer diagnosis, and more and more biomarkers have been developed.
Mutations in genes such as BRCA1 and BRCA2 may increase the risk of breast,
ovarian and other cancers, which have been used as biomarkers for cancer risk in
clinical practice. (Chen and Parmigiani, 2007) The findings from this study suggest
that dysfunctions or functional clocks may become the candidate of indicators of
cancer survival and therapeutic response outcomes. Biomarker testing can help
personalize the management of cancer and help cancer patients make better treatment
decisions, thereby reducing cancer mortality. The clinical applicability of biomarkers
is one of the most challenging parts of converting research results into practical
applications. In order to apply these results to maximize patient benefits, the
effectiveness of markers should be evaluated using the disciplined application of well-

designed clinical trials.
Uncovering the function of genes linked to cancer and finding less harmful ways
to improve cancer outcomes has long been the focus of cancer researchers around the
world. Currently, targeted therapy is the focal point of anticancer drug development.
Effective identification of potential targets that play essential roles in the growth and
survival of cancer cell is required by the realization of targeted therapies. In this study,
the significant associations between circadian genetic factors and cancer survival may
help find potential therapeutic targets for cancer. If activators of positive regulator
circadian genes or inhibitors of negative regulator circadian genes can be developed,
it may be possible to use them as treatments and effectively improve patients’
survival.
Understanding the role and relationship of clock genes in cancer provides an
important basis for the development of timed therapy for cancer. The influence of
circadian rhythm biology on the system level has been recognized in the field of
chronotherapy. In essence, the field seeks to understand how time of day affects the
efficacy, metabolism, toxicity, and off-target effects of therapeutic agents. (Levi and
Schibler, 2007) The concept of circadian-rhythm-based cancer treatment has also
developed rapidly, whose basic objective is to improve the effectiveness of
chemotherapy drugs as well as minimize adverse reactions through appropriate timing
of administration. Giacchetti et al. conducted a meta-analysis on the effects of
circadian chemotherapy on patients’ survival with metastatic colorectal cancer,
finding that overall survival was significantly improved in males on chrono

modulated chemotherapy (median values of 20.8 months) rather than on conventional
chemotherapy (median values of 17.5 months). (Giacchetti et al., 2012) Giving drugs
at a time with relative high expression level of positive regulator genes and low
expression level of negative regulator genes may facilitate the development of
effective new anticancer drugs or improved drug delivery plans and ultimately
improve patients’ health. By modeling, simulation of complex systems and clinical
trials, it may help determine the optimal model structure and parameters, as well as
the proper time. Currently, circadian rhythm studies are not yet a routine part of drug
safety and efficacy trials, and the effects of the duration on most drugs on the market
has not been widely explored. In the future, timed therapy focusing on circadian gene
expression may become a possible direction for improving cancer treatment in
clinical.

Conclusions
This study reviewed and demonstrated the significant associations between
circadian genetic factors and cancer survival across different cancer types. Although
results have been achieved in this area of research, clinical trials important to exploit
them have not yet been carried out. More research is warranted before circadian
genetic factors can be used as biomarkers of cancer survival outcomes.

Appendices
Table 1. Sample size for each cancer type in GENT2 and KM Plotter.
Database

Cancer Type

Sample Size

GENT2

breast cancer

502

blood cancer

554

brain cancer

50

colon cancer

1003

lung cancer

445

ovary cancer

166

stomach cancer

300

Bladder Carcinoma

405

Breast cancer

1090

Cervical squamous cell carcinoma

304

Esophageal Adenocarcinoma

80

Esophageal Squamous Cell Carcinoma

81

Head-neck squamous cell carcinoma

500

Kidney renal clear cell carcinoma

530

Kidney renal papillary cell carcinoma

288

Liver hepatocellular carcinoma

371

Lung adenocarcinoma

513

Lung squamous cell carcinoma

501

Ovarian cancer

374

Pancreatic ductal adenocarcinoma

177

Pheochromocytoma and Paraganglioma

178

Rectum adenocarcinoma

165

Sarcoma

259

Stomach adenocarcinoma

375

Testicular Germ Cell Tumor

134

Thymoma

119

Thyroid carcinoma

502

Uterine corpus endometrial carcinoma

543

KM Plotter

Table 2. Summary of significant associations between circadian genetic factors
and cancer survival.

Figure 1. A. The number of circadian factors related with cancer survival by

cancer type. B. The number of papers indicating associations between circadian
factors and cancer survival by cancer type.

Figure 2. The number of cancer types related to genetic circadian factors.

Figure 3. The Kaplan Meier survival curves for cancer patients with high and low circadian

gene expression using GENT2 database. It includes fifteen genes: PER1, PER2, PER3, CRY1,
CRY2, BMAL1, NPAS2, RORA, RORC, NR1D2, DEC1, TIPIN, CLOCK, NPAS3 and
TIMELESS.

Figure 4. The Kaplan Meier survival curves for cancer patients with high and low circadian
gene expression using Kaplan-Meier plotter database. It includes six genes: PER2, PER3,
RORA, RORC, DEC1 and TIMELESS.

Supplemental Figures
Figure 5. The Kaplan Meier survival curves for cancer patients with high and low circadian
gene expression using Kaplan-Meier plotter database.
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